PMID- 32462682
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20240109
IS  - 1745-4514 (Electronic)
IS  - 0145-8884 (Linking)
VI  - 44
IP  - 7
DP  - 2020 Jul
TI  - The role of mTOR and oral intervention of combined Zingiber officinale-Terminalia 
      chebula extract in type 2 diabetes rat models.
PG  - e13250
LID - 10.1111/jfbc.13250 [doi]
AB  - The present study examined the potential of Zingiber officinale-Terminalia 
      chebula extract alone (ZO and TC) and in combination (ZOTC) against type 2 
      diabetes via downregulation of mechanistic target of rapamycin (mTOR). The 1:4 
      (ZOTC) ratio showed high cell survival percentage against the rat insulinoma cell 
      line (RIN-5F) when compared to other possible ratios of ZOTC. Oral administration 
      of ZO alone, TC alone, combined ZOTC (1:4), and the positive control metformin 
      (Met) in fructose-streptozotocin (STZ) -induced diabetic rats showed reduced 
      blood glucose levels, reduced insulin resistance (HOMA-IR), increased insulin 
      levels, and increased pancreatic beta cell function (HOMA-beta). ZOTC treatment in 
      diabetic rats ameliorated the antioxidant status without affecting liver and 
      serum parameters. Histological evaluation of the pancreas was performed to find 
      pathological changes; the transcriptional and immunohistochemistry results showed 
      reduced mTOR expression in the pancreas during ZOTC treatment. Conclusively, the 
      results obtained suggest that ZOTC treatment against fructose-STZ-induced type 2 
      diabetes rat models can help regulate blood glucose, insulin levels, and 
      normalize pancreatic beta cell damage. PRACTICAL APPLICATIONS: Type 2 diabetes is a 
      chronic metabolic disorder that affects a large number of populations worldwide. 
      Zingiber officinale (ZO) and Terminalia chebula (TC) has been used in traditional 
      medicine since ancient times against various ailments, including diabetes. In 
      this study, we reported the effect of the combined ZOTC that showed significant 
      blood glucose reduction and increased insulin levels via mTOR when compared to 
      individual treatments. This finding is valuable for food technologists and 
      alternative medicine practitioners to know the antidiabetic effect of the ZOTC 
      combination.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Mathiyazhagan, Jayasindu
AU  - Mathiyazhagan J
AD  - School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 
      India.
FAU - Kodiveri Muthukaliannan, Gothandam
AU  - Kodiveri Muthukaliannan G
AUID- ORCID: 0000-0003-1576-5324
AD  - School of Bio Sciences and Technology, Vellore Institute of Technology, Vellore, 
      India.
LA  - eng
PT  - Journal Article
DEP - 20200527
PL  - United States
TA  - J Food Biochem
JT  - Journal of food biochemistry
JID - 7706045
RN  - 0 (Plant Extracts)
RN  - EC 2.7.1.1 (mTOR protein, rat)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Animals
MH  - *Diabetes Mellitus, Experimental/drug therapy
MH  - *Diabetes Mellitus, Type 2/drug therapy
MH  - *Zingiber officinale
MH  - Plant Extracts/pharmacology/therapeutic use
MH  - Rats
MH  - Rats, Wistar
MH  - Sirolimus
MH  - TOR Serine-Threonine Kinases
MH  - *Terminalia
OTO - NOTNLM
OT  - Terminalia chebula
OT  - Zingiber officinale
OT  - RIN-5F
OT  - mTOR
OT  - type 2 diabetes
EDAT- 2020/05/29 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/05/29 06:00
PHST- 2020/02/05 00:00 [received]
PHST- 2020/03/20 00:00 [revised]
PHST- 2020/03/31 00:00 [accepted]
PHST- 2020/05/29 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/05/29 06:00 [entrez]
AID - 10.1111/jfbc.13250 [doi]
PST - ppublish
SO  - J Food Biochem. 2020 Jul;44(7):e13250. doi: 10.1111/jfbc.13250. Epub 2020 May 27.